Bagel, J.; Armstrong, A. .; Warren, R.; Papp, K.; Thaçi, D.; Menter, A.; Cather, J.; Augustin, M.; Hippeli, L.; Daamen, C.; Griffiths, C. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial. J of Skin 2022, 6, s47.